Volasertib
Volasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 9 | 1 | 1 | — | — | 11 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 2 | 1 | — | — | 8 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 1 | 1 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 1 | — | — | — | 10 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 1 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Preleukemia | D011289 | — | — | 3 | — | — | — | — | 3 |
| Syndrome | D013577 | — | — | 3 | — | — | — | — | 3 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 2 | — | — | — | — | 2 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 1 | — | — | — | — | 1 |
| Monocytic leukemia acute | D007948 | — | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | — | — | — | — | 1 |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Volasertib |
| INN | volasertib |
| Description | Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.
|
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 755038-54-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1233528 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12062 |
| UNII ID | 6EM57086EA (ChemIDplus, GSRS) |
Target
Agency Approved
PLK1
PLK1
Organism
Homo sapiens
Gene name
PLK1
Gene synonyms
PLK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK1
Protein synonyms
cell cycle regulated protein kinase, PLK-1, polo (Drosophia)-like kinase, Polo-like kinase 1, Serine/threonine-protein kinase 13, STPK13
Uniprot ID
Mouse ortholog
Plk1 (18817)
serine/threonine-protein kinase PLK1 (Q07832)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,255 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use